A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: A 44-week, double-blind, continuation study

Canadian Journal of Psychiatry

Volumn 54, Issue 1, 2009, Pages 46-54

  Addington, Donald E ^a,b   Labelle, Alain ^c,d   Kulkarni, Jayashri ^e,f   Johnson, Gordon ^g   Loebel, Antony ^h,i   Mandel, Francine S ^h  

^a UNIVERSITY OF CALGARY   (Canada)

^b FOOTHILLS HOSPITAL   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d ROYAL OTTAWA HOSPITAL   (Canada)

^e MONASH UNIVERSITY   (Australia)

^f MONASH UNIVERSITY   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h PFIZER INC   (United States)

ⁱ Dainippon Sumitomo Pharma America Inc   (United States)

Author keywords

Double blind clinical trial; Efficacy; Long term treatment; Risperidone; Safety and tolerability; Schizophrenia; Ziprasidone

Indexed keywords

LORAZEPAM; PROPRANOLOL DERIVATIVE; RISPERIDONE; TEMAZEPAM; ZIPRASIDONE;

ADULT; AGITATION; AKATHISIA; ANXIETY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HEART DISEASE; HUMAN; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; MUSCLE HYPERTONIA; NAUSEA; POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY TRACT INFECTION; SALIVATION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIC REACTION; SIDE EFFECT; SOMNOLENCE; TREATMENT RESPONSE; TREMOR; VOMITING; WEIGHT GAIN;

EID: 60849123153     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674370905400108     Document Type: Article

References (32)

1. Ayuso-Gutierrez JL, del Rio Vega JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res. 2007;28:199-206.
2. Kane JM. Schizophrenia. N Engl J Med. 1996;334(1):34-41.
3. Rummel C, Hamann J, Kissling W, et al. New generation antipsychotics for first episode schizophrenia (Cochrane Review). In: The Cochrane Library. Issue 2. Chichester (UK): John Wiley & Sons, Ltd; 2004.
4. Duggan L, Fenton M, Dardennes RM, et al. Olanzapine for schizophrenia (Cochrane Review). In: The Cochrane Library. Issue 2. Chichester (UK): John Wiley & Sons, Ltd; 2004.
5. Hunter RH, Joy CB, Kennedy E, et al. Risperidone versus typical antipsychotic medication for schizophrenia (Cochrane Review). In: The Cochrane Library. Issue 2. Chichester (UK): John Wiley & Sons, Ltd; 2004.
6. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-1696.
7. Kinon BJ, Gilmore JA, Liu H, et al. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology. 2003;28(Suppl 2):69-82.
8. Arato M, O'Connor R, Meltzer HY. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol. 2002;17(5):207-215.
9. Hirsch SR, Kissling W, Bauml J, et al. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry. 2002;63(6):516-523.
10. Simpson GM, Weiden P, Pigott T, et al. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry. 2005;162(8):1535-1538.
11. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997;17(5):407-418.
12. Sechter D, Peuskens J, Fleurot O, et al. Amisulpride vs risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology. 2002;27(6):1071-1081. Erratum appears in Neuropsychopharmacology. 2003;28:611.
13. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. Neuropsychopharmacology2002;346(1):16-22. Erratum appears in N Engl J Med. 2002;346:1424.
14. Addington DE, Pantelis C, Dineen M, et al. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry. 2004;65(12):1624-1633.
15. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
16. Gureje O, Miles W, Keks N, et al. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophr Res. 2003;61(2-3):303-314.
17. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1050-1060.
18. Mullins CD, Obeidat NA, Cuffel BJ, et al. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophr Res. 2008;98(1-3):8-15.
19. Nemeroff CB, Lieberman JA, Weiden PJ, et al. From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr. 2005;10(11):S1-S20.
20. Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004;161(5):818-825.
21. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology. 1999;20(5):491-505.
22. Keck P Jr, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlledtrial. Psychopharmacology(Berl). 1998;140(2):173-184.
23. Mullins CD, Shaya FT, Zito JM, et al. Effect of initial ziprasidone dose on treatment persistence in schizophrenia. Schizophr Res. 2006;83(2-3):277-284.
24. Joyce AT, Harrison DJ, Loebel AD, et al. Effect of initial ziprasidone dose on length of therapy in schizophrenia. Schizophr Res. 2006;83(2-3):285-292.
25. Williams R. Optimal dosing with risperidone: updated recommendations. J Clin Psychiatry. 2001;62(4):282-289.
26. Kane JM, Leucht S, Carpenter D, et al. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64(Suppl 12):5-19.
27. Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatry. 2002;10(5):280-291.
28. Risperdal [package insert]. Titusville (NJ): Janssen Pharmaceuticals; 2007.
29. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151(6):825-835.
30. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry. 1995;166(6):712-726.
31. Halbreich U, Kinon BJ, Gilmore JA, et al. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology. 2003;28(Suppl 1):53-67.
32. Gilbody SM, Bagnall AM, Duggan L, et al. Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review). In: The Cochrane Library. Issue 2. Chichester (UK): John Wiley & Sons, Ltd; 2007.